fbpx

molecules of the month

MAK683

oral, allosteric PRC2 inhibitor (EED)

in Ph. I/II for cancer (DLBCL); preliminary efficacy

from micromolar HTS hit

J. Med. Chem.

Novartis, Emeryville, CA

oral, allosteric PRC2 inhibitor (EED) - Novartis, Emeryville, CA
4 mins read

Context. MAK683 is an oral, allosteric and selective PRC2 inhibitor intended for PRC2-dependent cancers. PRC2 is an essential epigenetic regulator of gene expression and enhanced or diminished PRC2 function have been implicated in a number of cancers. Enhancer of zeste homolog 2 (EZH2), one of the four core components of PRC2 that directly trimethylates K27 of histone 3 (H3K27me3), has been the most extensively studied PRC2 subunit and a number of EZH2 mutations and post-translational modifications have reportedly been associated with disease progression. In addition, the approval of the first EZH2 inhibitor, Epizyme’s tazemetostat, for advanced/metastatic epithelioid sarcoma and relapsed/refractory follicular lymphoma further validated EZH2 and other PRC2 components as viable drug targets. Resistance mechanisms to EZH2 inhibitors have been…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: